SPECIALTY QUANTITY LIMIT PROGRAM

GALAFOLD (migalastat)

I. PROGRAM DESCRIPTION


The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of Fabry disease with an amenable galactosidase alpha gene (GLA) variant fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Galafold (migalastat) 123 mg capsules	14 per 28 days	123 mg orally once every other day at the same time of day

III. REFERENCE

1. Galafold [package insert]. Cranbury, NJ: Amicus Therapeutics U.S., Inc.; August 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of